SignNow vs DocuSign for Research and Clinical Offices

If you are comparing SignNow and DocuSign for a research office, a clinical trials unit, or a sponsored-programs team, the feature grids on both vendors’ sites will not decide it for you. Both products sign documents competently. What actually decides an institutional purchase is a much shorter list: whether the vendor will sign a Business Associate Agreement, what the audit trail records and whether it holds up as evidence of intent, whether SAML single sign-on costs you a tier upgrade, and what the bill really looks like once envelope allowances are exhausted.

This page compares the two on those criteria. We do not sell either product, and we have no commercial relationship with SignNow or DocuSign — which is exactly why we can tell you plainly that for a large share of research offices, DocuSign is the right answer and you should stop shopping. We also cover the specific case where neither fits, and name the tool we think does.

Tip: try code CASRAI at checkout for 15% off, if the offer is currently active for this program — codes vary by vendor and aren’t guaranteed.

The short answer

Three decision rules cover most research offices:

• Your institution already holds a DocuSign enterprise agreement. Use it. Do not buy a second signature tool. The per-seat saving from switching will not survive the duplicate vendor-risk assessment, the second security review, and the year of counterparties asking why the envelope did not come from the system they recognise.
• You have many seats, steady volume, and no protected health information. SignNow is materially cheaper per seat and the gap widens with headcount. This is the case SignNow is built to win.
• You have few seats but bursty, high document volume — a grants office that sends four envelopes in July and four hundred in September, a lab that runs MTAs in waves — and no BAA requirement. Both incumbents misprice you, because both meter envelopes per user per year. That is the gap Sign.Plus fills, and we come back to it at the end.

Everything below is the reasoning behind those rules.

At a glance

Figures verified in August 2026. Read the sourcing note at the foot of this page before quoting any of them internally — the three columns are not equally well-sourced.

What actually decides this purchase

Signature products converge on features fast. Templates, reusable fields, bulk send, reminders, mobile signing, conditional routing — assume all three products in this comparison do these adequately, because they do. The differentiators that survive a procurement review are narrower:

1. Will the vendor sign a BAA, and on which plan? If any envelope will ever carry protected health information, this is a gate, not a preference.
2. What does the audit trail actually capture? Under ESIGN and UETA, the legal question in a dispute is almost never “is an electronic signature valid” — it is “can you show this specific person intended to sign this specific document.” That is an evidence question about the certificate, not a feature question.
3. Does SSO cost a tier jump? Most university identity teams will not provision a tool that cannot do SAML. If SSO lives on the top plan, your real price is the top plan.
4. What is the envelope allowance, and what does an overage cost? This is where quoted per-seat prices stop predicting the invoice.
5. Counterparty familiarity. Underrated and genuinely worth money. An industry sponsor’s legal department that already accepts DocuSign will not run a security review on it. Negotiation time is the most expensive thing in a research office.

See Sign.Plus pricing and limits →

SignNow vs DocuSign: real cost at 5, 15 and 40 users

Prices below are list prices as published by each vendor, verified in August 2026. Read the sourcing note under the table before you quote any of these numbers internally — they are not all equally well-established.

DocuSign eSignature, from Docusign’s own plans page (verified August 2026, USD, annual commitment billed monthly): Personal at $11/month for a single user with 5 envelopes per month; Standard at $30/user/month with 100 envelopes per user per year, up to 50 users; Business Pro at $45/user/month, also 100 envelopes per user per year, up to 50 users. Above 50 users you are into “Enhanced Plans”, which are quote-only. Critically, Docusign’s own plans page lists SSO, HIPAA support through a BAA, 21 CFR Part 11 support and FedRAMP as available only on those quote-only Enhanced plans — not on Standard or Business Pro.

SignNow is the weaker half of this comparison for sourcing, and we want to be straight about why. SignNow’s public pricing page redirects to a commerce application that did not return readable content to us, so we could not verify its figures from the vendor directly. The numbers that follow are reported by third-party pricing aggregators in 2026 and should be treated as indicative, not vendor-confirmed: a Business tier around $8/user/month, Business Premium around $15/user/month and Enterprise around $30/user/month on annual billing, with 100 signature invites per user per year on those standard tiers and per-invite overage charges reported at roughly $0.96, $1.80 and $3.60 respectively. HIPAA compliance with a BAA is reported to sit only on SignNow’s quote-only Site License plan. Confirm every one of these figures with SignNow directly before building a business case on them.

What the comparison looks like once you do the arithmetic, using the reported SignNow figures:

• 5 users. The per-seat gap is real but small in absolute terms — a few thousand dollars a year between SignNow Business and DocuSign Standard. At this size, counterparty familiarity and the cost of your own team’s time usually outweigh the saving. Do not switch platforms to save this.
• 15 users. The gap becomes material, and this is the size at which a genuine bake-off is worth running. It is also the size at which the envelope allowance starts to bind: 15 users on either standard plan gives you 1,500 envelopes a year in aggregate, which sounds generous until a single sub-award cycle eats a third of it.
• 40 users. SignNow’s per-seat advantage is large enough to be a budget line. But check two things before you act on it: whether you are about to cross the 50-user ceiling into quote-only pricing on either platform, and whether any of those 40 seats touch PHI — because if they do, both products move you to a quote-only tier and the published per-seat comparison stops being the comparison you are actually running.

The general lesson: the per-seat headline price predicts the invoice only for offices with steady, moderate volume and no compliance requirements. For everyone else, the tier that carries your compliance requirement is your real price.

Is SignNow HIPAA compliant, and will it sign a BAA?

“HIPAA compliant” is not a property a software product has on its own. Under the HIPAA Privacy and Security Rules, a vendor that creates, receives, maintains or transmits protected health information on behalf of a covered entity is a business associate, and the covered entity must have a written Business Associate Agreement in place with them (45 CFR 164.502(e) and 164.308(b)). A product with strong encryption and no signed BAA does not satisfy that requirement. A product with a signed BAA and the same encryption does.

So the operative question is not “is SignNow HIPAA compliant” but “on which plan will SignNow sign a BAA, and what does that plan cost.” Third-party sources reported in 2026 that this sits on SignNow’s Site License plan, which is quote-only. Docusign’s own plans page puts HIPAA support through a BAA on its Enhanced plans, also quote-only. Sign.Plus publishes it on its Enterprise plan at a listed price.

The practical consequence for a research office: if PHI is in scope, none of the published per-seat prices in the previous section apply to you. You are getting a quote from at least two of these three vendors, and your comparison is between quotes, not between price pages. Budget for that conversation rather than for the list price. Our guides on HIPAA-compliant e-signature software and HIPAA-compliant e-signatures go into the selection criteria in more depth.

One caution worth stating plainly: a BAA covers the vendor relationship. It does not make your workflow compliant. Sending a consent form to a personal email address, or leaving completed envelopes in a shared folder, is a breach regardless of what the vendor signed.

Audit trails compared: what each records, and what holds up as evidence of intent

Under the US ESIGN Act and state adoptions of UETA, an electronic signature cannot be denied legal effect merely because it is electronic. That is a much lower bar than most buyers assume, and it is not where disputes are actually won or lost. When a signature is challenged, the question is attribution and intent: was it this person, did they see this document, did they mean to be bound.

All three products in this comparison generate a completion certificate — a document recording the events in the signing session. The details that matter when a certificate is read by someone hostile to it:

• Identity evidence beyond the email address. An emailed link proves control of an inbox. Access codes, SMS one-time passcodes, or knowledge-based authentication raise the bar. All three vendors offer some form of additional authentication; what varies is which tier it sits on.
• Tamper evidence on the completed document. A cryptographic seal applied at completion is what lets you demonstrate the PDF has not changed since signing. This is the single most useful property of the certificate and is standard across all three.
• Event granularity and timestamping. Sent, viewed, signed, completed, with timestamps and IP addresses per event, is the normal baseline.
• Whether the certificate travels with the document. A certificate you have to log in to retrieve is a certificate your counterparty’s counsel will not see. Ones embedded in or attached to the completed PDF are more useful in practice.

None of the three is deficient here, and we are not going to invent a scoring difference that we did not measure. The honest guidance is procedural rather than comparative: before you sign a contract with any of them, run a test envelope, download the completion certificate, and show it to whoever would have to rely on it — your contracts office, your general counsel, or your sponsor’s legal team. That fifteen-minute exercise tells you more than any comparison table, including this one. If your office is still deciding whether electronic signatures are appropriate at all for a given document class, our guide on wet signatures vs electronic signatures covers where wet ink is still required.

SSO, provisioning, and what your identity team will require

This is the criterion that most often changes the answer late in a procurement, because it is usually raised by a team that was not in the original evaluation.

Most university and health-system identity teams have a standing requirement that any tool holding institutional records authenticate through the institutional identity provider via SAML, and increasingly that it support SCIM provisioning so that leavers are deprovisioned automatically. If your evaluation priced a mid-tier plan and your identity team then requires SSO, your real price is whatever tier carries SSO.

As of August 2026: Docusign’s own plans page shows SSO as “Contact sales”, available on Enhanced plans — it is not listed as included on Standard or Business Pro. Sign.Plus publishes Single Sign-On on its Enterprise plan. For SignNow, we could not verify SSO tier placement from the vendor and the aggregator sources we consulted did not state it clearly, so we are not going to assert it — ask SignNow directly, and get the answer in writing before you sign.

Practical advice: bring your identity and security teams into the evaluation in week one, not week six. The single most common way these purchases go wrong is a well-run functional evaluation that selects a tier which is then invalidated by a requirement nobody asked about until contracting.

Compare Sign.Plus plans and limits →

Envelope and send limits, overages, and the bill nobody forecasts

This is the most under-examined line in an e-signature purchase, and the one most likely to embarrass whoever built the budget.

Both incumbents meter the same way. Docusign’s published Standard and Business Pro plans allow 100 envelopes per user per year. SignNow’s standard tiers are reported to allow 100 signature invites per user per year, with per-invite overage charges once you exceed it. The allowance is pooled across your users in practice, but it is sized by headcount — which is fine if your document volume scales with your headcount, and badly wrong if it does not.

Research offices are a textbook case where it does not. Consider:

• A sponsored-programs office of six people that processes several hundred sub-award amendments in a single funding cycle.
• A core facility with two administrators that sends a service agreement to every user of the facility.
• A trials unit whose consent volume is set by enrolment, not by staffing.

In each case the seat count is small and the envelope count is large, and the per-user allowance model prices you badly. At 6 users on a 100-per-user-per-year plan you have 600 envelopes; a busy cycle exhausts that and every subsequent envelope is billed at an overage rate that was never in the budget.

What to do about it: before you request a quote, count last year’s actual signature volume from whatever you use now — even if that is emailed PDFs. Divide by planned seats. If the result is meaningfully above 100, the per-user-metered plans are the wrong shape for you and you should say so explicitly in the procurement, because it changes which products are even candidates.

Simple, advanced and qualified signatures: where each product stops

If any of your agreements are governed by EU or UK law, or you collaborate with EU institutions, the eIDAS framework matters. eIDAS (Regulation (EU) No 910/2014, as amended by Regulation (EU) 2024/1183) recognises three tiers:

• Simple electronic signature (SES) — data in electronic form used to sign. The lowest bar; what most click-to-sign flows produce.
• Advanced electronic signature (AdES) — uniquely linked to and capable of identifying the signatory, created using data the signatory can use under their sole control, and linked to the data such that later changes are detectable.
• Qualified electronic signature (QES) — an AdES created by a qualified signature creation device and based on a qualified certificate issued by a trust service provider on an EU trusted list. A QES has the legal equivalence of a handwritten signature across all member states.

Most research agreements do not require QES. Some do — certain public-procurement filings, some national regulatory submissions, and occasionally a specific institution’s own policy. If yours do, treat it as a hard gate and verify it product by product, at tier level, in writing.

A correction to a claim we have seen made elsewhere, including in our own earlier brief for this page: Sign.Plus’s pricing page lists eIDAS, ZertES and QES among its compliance standards. We have not independently verified at which tier QES is available, through which qualified trust service provider, or for which jurisdictions. So we are not going to tell you Sign.Plus cannot do QES — and we are equally not going to tell you it can. If QES is a requirement, ask all three vendors to name the qualified trust service provider and the applicable EU trusted list entry, and do not accept a compliance badge as an answer. Docusign’s own plans page similarly puts QES under “Contact sales” on Enhanced plans.

Which fits IRB consent, sub-award agreements, and MTAs

The document class changes the answer more than the vendor does.

IRB-approved informed consent. This is the highest-stakes category and the one where you should be most conservative. If the research is FDA-regulated, electronic records and signatures fall under 21 CFR Part 11, which is a system-validation requirement, not a feature checkbox — you need documented validation, audit trails, and controls over record retention. Docusign publishes 21 CFR Part 11 support on its quote-only Enhanced plans. Neither SignNow’s standard tiers nor Sign.Plus is presented by its vendor as a validated Part 11 system, and you should not treat either as one without written confirmation. Our guides on the informed consent process and Part 11 validation cover what validation actually involves. For non-FDA-regulated human-subjects research, the bar is your IRB’s, and you should ask them before you buy, not after.

Sub-award agreements and amendments. High volume, moderate stakes, many external signers who have no account with your vendor. The deciding factors here are external-signer experience and envelope economics, not compliance tier. All three handle account-less external signing; the volume question from the previous section is what should drive the decision.

Material transfer agreements. Bursty, often international, frequently signed by a counterparty’s technology transfer office that has its own preferred platform. Counterparty familiarity matters most here, which tilts toward DocuSign — not because it is technically better, but because the other side’s TTO has already approved it.

When neither is right: the seat-light, burst-volume case

There is a specific, common configuration that both SignNow and DocuSign price badly, and it is worth naming because a lot of research offices are in it:

A small number of named senders, no protected health information, no FDA-regulated records, no QES requirement — and document volume that is high, irregular, and completely disconnected from headcount.

Both incumbents meter envelopes per user per year. If you have four senders and three thousand documents, per-user metering is the wrong shape, and you will either overbuy seats you do not need or pay overages you did not forecast.

Sign.Plus, from Alohi, prices differently. As of August 2026, its published plans (listed in euro on the pricing page we retrieved — confirm the currency and rate for your billing country) are: Personal at €9.99/month for one user with 10 signature requests per month; Professional at €19.99/user/month for up to 5 users with unlimited signature requests; Business at €29.99/user/month, also unlimited; and Enterprise at €49.99/user/month with unlimited requests plus Single Sign-On and HIPAA compliance with a BAA. Its published compliance list includes ISO 27001, SOC 2, GDPR, CCPA, PCI DSS, ESIGN, eIDAS and ZertES.

The relevant number is the Professional tier: unlimited signature requests, from the second-cheapest plan, for up to five users. For the seat-light burst-volume office described above, that removes the envelope-allowance problem entirely rather than pricing around it. Our fuller Sign.Plus review covers the product itself in more depth, and our DocuSign alternatives guide sets it against the wider field.

Who Sign.Plus is not right for — and what to use instead

We would rather you not buy it than buy it and find out. Sign.Plus is the wrong choice if:

• You need a validated 21 CFR Part 11 system for FDA-regulated records. Use Docusign’s Enhanced plans, or a purpose-built regulated-content platform. Do not improvise this one.
• You need deep ERP, CRM or CTMS integration. DocuSign’s integration breadth is genuinely its strongest advantage and it is not close. If the signature step has to live inside Salesforce, Workday, or your grants system, that is a DocuSign argument.
• Your counterparties are industry sponsors and pharmaceutical legal departments. DocuSign passes without a security review. That is worth more than a per-seat saving, every time.
• You need HIPAA coverage on a small budget. Sign.Plus puts HIPAA and a BAA on its Enterprise tier at €49.99/user/month — which is more per seat than Docusign Standard’s list price. Sign.Plus’s advantage is unlimited volume, not cheap compliance. If you need a BAA, get quotes from all three and compare quotes, not price pages.
• You have high, steady volume across many seats and no compliance gate. That is SignNow’s case, on cost, assuming the reported figures hold up when you confirm them.
• Your institution already has a DocuSign enterprise agreement. Stop. Use it.

If, having read all of that, you are in the seat-light, burst-volume, no-PHI case — the one both incumbents genuinely misprice — Sign.Plus is worth a trial.

Try Sign.Plus free →

Frequently asked questions

Is SignNow HIPAA compliant?

No product is “HIPAA compliant” on its own. What matters is whether the vendor will sign a Business Associate Agreement, because a covered entity must have a written BAA with any vendor that handles protected health information on its behalf (45 CFR 164.502(e), 164.308(b)). Third-party sources reported in 2026 that SignNow offers a BAA only on its quote-only Site License plan. We could not verify this from SignNow directly, so confirm it with the vendor in writing before budgeting.

Which is cheaper, SignNow or DocuSign?

On published and reported list prices, SignNow is cheaper per seat and the gap widens with headcount. But that comparison only holds if you need no compliance tier: both vendors put HIPAA/BAA behind quote-only plans, and Docusign also puts SSO, 21 CFR Part 11 and FedRAMP there. If any of those are requirements, you are comparing two quotes, not two price pages, and the per-seat headline stops predicting the invoice.

How many envelopes do you get, and what happens when you run out?

DocuSign Standard and Business Pro both allow 100 envelopes per user per year (verified August 2026). SignNow standard tiers are reported to allow 100 signature invites per user per year with per-invite overage charges. The trap for research offices is that the allowance is sized by headcount while document volume is often driven by funding cycles or enrolment instead. Count last year’s actual volume, divide by planned seats, and if the result is well above 100, say so in the procurement.

Do we need a qualified electronic signature (QES) under eIDAS?

Usually not. eIDAS recognises simple, advanced and qualified electronic signatures, and most research agreements are satisfied well below the qualified tier. QES matters for certain public-procurement filings, some national regulatory submissions, and occasionally a specific institution’s policy. If it applies to you, treat it as a hard gate and ask each vendor to name the qualified trust service provider and the EU trusted list entry — do not accept a compliance badge as an answer.

Can we use any of these for IRB-approved informed consent?

Ask your IRB before you buy, not after. If the research is FDA-regulated, electronic records and signatures fall under 21 CFR Part 11, which requires a validated system with documented controls, not just a feature. Docusign publishes Part 11 support on its quote-only Enhanced plans. Neither SignNow’s standard tiers nor Sign.Plus is presented by its vendor as a validated Part 11 system, and neither should be treated as one without written confirmation.

We already have a DocuSign enterprise agreement. Is it worth adding a cheaper tool?

Almost never. The marginal per-seat saving rarely survives a second vendor-risk assessment, a second security review, and the ongoing cost of counterparties asking why the envelope did not arrive from the platform they recognise. Use the agreement you have.

Where does Sign.Plus actually win?

One specific case: few named senders, high and irregular document volume disconnected from headcount, and no PHI, Part 11 or QES requirement. Both incumbents meter envelopes per user per year, which prices that shape badly. Sign.Plus Professional includes unlimited signature requests for up to five users. It does not win on compliance — its HIPAA tier costs more per seat than DocuSign Standard’s list price — and it does not win on integration breadth or counterparty recognition.

How we verified this, and what we could not

Transparency about sourcing is the only thing that makes a comparison page worth reading. As of August 2026:

• Vendor-verified: Docusign eSignature plan names, prices, envelope allowances, seat limits and the tier placement of SSO, HIPAA/BAA, 21 CFR Part 11 and FedRAMP, from Docusign’s own plans-and-pricing page. Sign.Plus plan names, prices, user counts, signature-request limits, and the tier placement of SSO and HIPAA/BAA, from Sign.Plus’s own pricing page.
• Reported, not vendor-verified: all SignNow pricing, invite allowances, overage rates and BAA tier placement. SignNow’s public pricing URL redirects to a commerce application that did not return readable content to us. These figures come from third-party pricing aggregators published in 2026 and are indicative only. Treat them as a starting point for a conversation with SignNow, not as a quote.
• Not verified and deliberately not asserted: SignNow’s SSO tier placement; the tier, trust service provider and jurisdictions for Sign.Plus’s QES support.

Prices and tier placements for all three vendors change without notice, and enterprise pricing is negotiated. Verify against each vendor’s current page before committing budget.